CD19-Directed CAR T-Cell Therapy Leads to Exceptionally Long Remissions in Some Patients with Relapsed or Refractory B-Cell non-Hodgkin Lymphomas By Ogkologos - July 16, 2026 3 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from 10-year follow-up of a phase II study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Welcomes the WHO Global Status Report on Cancer with Key Recommendations for Equitable Cancer Care Lorlatinib Continues to Show Long-Term Benefit in Newly-Diagnosed Patients with Advanced ALK-positive NSCLC GLP-1 Receptor Agonist Use Associated with a Significantly Lower Short-Term Incidence of Obesity-Associated Cancers Among Obese Individuals Without Diabetes MOST POPULAR ESMO Targeted Anticancer Therapies Congress 2025, Paris, France, 3-5 March February 24, 2025 News digest – sponge on a string, junk food watershed, prostate... August 1, 2020 EMA Recommends Granting a Conditional Marketing Authorisation for Autologous Anti-CD19-Transduced CD3+... October 22, 2020 Olive Oil Found to Reduce Risk of Death from Dementia, Cancer,... January 13, 2022 Load more HOT NEWS Increased Risk of Haematologic Malignancies Among Children and Adolescents Exposed to... FDA Grants Traditional Approval to Tarlatamab-dlle for Extensive Stage Small Cell... 2026 ESMO Breast Cancer Award Recipient Announced Efficacy of Sintilimab in the Adjuvant Treatment for Patients with Resected,...
